[HTML][HTML] Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma

T Kosaka, Y Yatabe, R Onozato, H Kuwano… - Journal of Thoracic …, 2009 - Elsevier
Introduction: Although mutation of the epidermal growth factor receptor (EGFR) gene is
predictive for the response to EGFR-tyrosine kinase inhibitor, its prognostic impact for …

Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma

YJ Lee, IK Park, MS Park, HJ Choi, BC Cho… - Journal of cancer …, 2009 - Springer
Purpose Although epidermal growth factor receptor (EGFR) tyrosine kinase (TK) mutations
are highly predictive of response to EGFR TK inhibitors in advanced non-small-cell lung …

Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas

W Liu, L Zhao, Q Pang, Z Yuan, B Li, P Wang - Medical oncology, 2014 - Springer
The purpose of this study was to evaluate the association between epidermal growth factor
receptor (EGFR) mutations and prognosis in patients with completely resected lung …

[HTML][HTML] Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma

C Deng, Y Zhang, Z Ma, F Fu, L Deng, Y Li… - The Journal of thoracic …, 2021 - Elsevier
Background Mutation of the EGFR gene is known as a predictor for the response to EGFR
tyrosine kinase inhibitor. Although EGFR mutation status is proposed to be incorporated in …

Clinical impacts of EGFR mutation status: analysis of 5780 surgically resected lung cancer cases

K Suda, T Mitsudomi, Y Shintani, J Okami, H Ito… - The Annals of thoracic …, 2021 - Elsevier
Background To elucidate the clinical, pathologic, and prognostic impacts of epidermal
growth factor receptor (EGFR) mutation and mutation subtypes in early-stage lung cancer …

[HTML][HTML] Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma

JL Marks, S Broderick, Q Zhou, D Chitale, AR Li… - Journal of thoracic …, 2008 - Elsevier
Background Somatic mutations in EGFR (exons 19 and 21) and KRAS (exon 2) are found in
lung adenocarcinomas and have potential prognostic value in patients with advanced …

Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung

YT Kim, T Kim, DS Lee, SJ Park, J Park, SJ Seo… - Lung Cancer, 2008 - Elsevier
Recent studies have reported that clinical response to epidermal growth factor receptor
(EGFR) inhibitors is associated with somatic changes of EGFR in the advanced stage of lung …

Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma

M Yotsukura, H Yasuda, T Shigenobu, K Kaseda… - Lung Cancer, 2017 - Elsevier
Objectives Over the past decade, the biological and clinical characteristics of lung cancer
with epidermal growth factor receptor (EGFR) mutation have been well studied. However …

[HTML][HTML] Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib

SP D'Angelo, YY Janjigian, N Ahye, GJ Riely… - Journal of Thoracic …, 2012 - Elsevier
Background: EGFR and KRAS mutations are mutually exclusive and predict outcomes with
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in patients …

[HTML][HTML] The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non–small-cell …

YT Kim, YW Seong, YJ Jung, YK Jeon, IK Park… - Journal of Thoracic …, 2013 - Elsevier
Background The presence of mutation in EGFR gene is known as a predictive marker for the
response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) …